Home » Stocks » ONCT

Oncternal Therapeutics, Inc. (ONCT)

Stock Price: $5.40 USD -0.01 (-0.18%)
Updated Mar 8, 2021 4:00 PM EST - Market closed
After-hours: $5.55 +0.15 (2.78%) Mar 8, 7:26 PM
Market Cap 263.83M
Revenue (ttm) 2.52M
Net Income (ttm) -18.82M
Shares Out 20.13M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $5.40
Previous Close $5.41
Change ($) -0.01
Change (%) -0.18%
Day's Open 5.43
Day's Range 5.31 - 5.86
Day's Volume 797,400
52-Week Range 1.49 - 8.65

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, tod...

Zacks Investment Research - 3 weeks ago

5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty

Other stocks mentioned: ORGO, RDUS, TPTX, USNA
Seeking Alpha - 1 month ago

Oncternal has solid data for cirmtuzumab+ibrutinib in MCL and CLL. It has cash it says is enough for 2 years.

Seeking Alpha - 1 month ago

Oncternal has potential winner with cirmtuzumab in mantle cell lymphoma. A potential pediatric review voucher for TK216 in Ewing sarcoma alone is worth $80-150 million.

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, tod...

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, tod...

GlobeNewsWire - 2 months ago

SAN DIEGO and STOCKHOLM, Sweden, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel o...

GlobeNewsWire - 2 months ago

SAN DIEGO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, tod...

GlobeNewsWire - 2 months ago

SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, tod...

GlobeNewsWire - 2 months ago

SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, tod...

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, tod...

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, tod...

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, tod...

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a co...

GlobeNewsWire - 4 months ago

SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, tod...

Business Wire - 5 months ago

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that...

Business Wire - 5 months ago

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the ...

Business Wire - 5 months ago

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that manag...

Business Wire - 6 months ago

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that...

Business Wire - 6 months ago

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that...

Seeking Alpha - 7 months ago

Oncternal Therapeutics' (ONCT) CEO Jim Breitmeyer on Q2 2020 Results - Earnings Call Transcript

Business Wire - 7 months ago

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a bus...

Business Wire - 7 months ago

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that...

Business Wire - 7 months ago

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that...

Business Wire - 7 months ago

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that...

Business Wire - 8 months ago

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that...

Business Wire - 8 months ago

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an u...

Seeking Alpha - 9 months ago

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2020 Earnings Conference Call May 7, 2020 5:00 PM ET

Seeking Alpha - 11 months ago

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2019 Results Conference Call March 16, 2020 4:30 PM ET

About ONCT

Oncternal Therapeutics, a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. The company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ROR1) that is in Phase I/II clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in Phase Ib clinical trial in combination with paclitaxel for the treatmen... [Read more...]

Industry
Biotechnology
CEO
James Breitmeyer
Employees
11
Stock Exchange
NASDAQ
Ticker Symbol
ONCT
Full Company Profile

Financial Performance

In 2019, ONCT's revenue was $2.43 million, a decrease of -3.81% compared to the previous year's $2.52 million. Losses were -$34.19 million, 419.7% more than in 2018.

Financial Statements